To corroborate the hypothesis of CD36 in promoting a reduction in fatal outcomes in TsV envenoming, the authors demonstrated in another study that the use of EP80137 (an agonist of the scavenger receptor CD36–0.289 μmol/kg, intraperitoneally) promoted an increase in the production of LTB4, a decrease in IL-1β, and a reduction in mortality and pulmonary edema in a murine envenoming model challenged with a lethal dose of TsV (Zoccal et al., 2019). This evidence concerns the gene IL1B and edema.